<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336722</url>
  </required_header>
  <id_info>
    <org_study_id>A4250-011</org_study_id>
    <nct_id>NCT04336722</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and
      safety of odevixibat compared to placebo in children with biliary atresia who have undergone
      a Kasai hepatoportoenterostomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 70 sites will be initiated for this study in North America, Europe, Middle East, and
      Asia Pacific.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with liver transplant</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Proportion of patients who are alive and have not undergone a liver transplant after 104 weeks of study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of any sentinel events</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Time to onset of any sentinel events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin levels</measure>
    <time_frame>From baseline to Weeks 13, 26, 52 and 104</time_frame>
    <description>Total bilirubin level after 13, 26, 52, and 104 weeks of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bile acid levels</measure>
    <time_frame>From baseline to Weeks 13, 26, 52 and 104</time_frame>
    <description>Serum bile acid level after 13, 26, 52, and 104 weeks of study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Biliary Atresia</condition>
  <arm_group>
    <arm_group_label>Odevixibat (A4250)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules for oral administration once daily for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules for oral administration (to match active) once daily for 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Odevixibat</intervention_name>
    <description>Odevixibat is a small molecule and selective inhibitor of IBAT.</description>
    <arm_group_label>Odevixibat (A4250)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo identical in appearance to experimental drug (odevixibat).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female patient with a clinical diagnosis of BA

          -  Age at Kasai HPE ≤90 days

          -  Eligible to start study treatment within 3 weeks post-Kasai HPE

        Key Exclusion Criteria:

          -  Patients with intractable ascites

          -  Ileal resection surgery

          -  ALT ≥10× upper limit of normal (ULN) at screening

          -  Patient on total parenteral nutrition at randomization

          -  Acute ascending cholangitis (patients may be randomized after resolution of acute
             ascending cholangitis)

          -  Choledochal cystic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>111 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Albireo</last_name>
    <phone>+1 (857) 378-2035</phone>
    <email>medinfo@albireopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preeti Malik</last_name>
      <phone>718-741-2557</phone>
      <email>malik@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Nadia Ovchinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Blasko</last_name>
      <email>Blaskoa2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick McKiernan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kasai</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Atresia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

